Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. more
Time Frame | PMCB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.83% | 0.31% | -1.26% |
1-Month Return | -9.47% | 0.6% | -4.16% |
3-Month Return | -11.56% | -9.44% | -0.46% |
6-Month Return | -25.73% | -5.15% | 3.58% |
1-Year Return | -29.21% | 0.33% | 22.47% |
3-Year Return | -36.78% | 4.53% | 25.13% |
5-Year Return | -97.97% | 35.98% | 77.7% |
10-Year Return | -99.37% | 100.72% | 190.12% |
Apr '20 | Apr '21 | Apr '22 | Apr '23 | Apr '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Gross Profit | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Operating Expenses | 3.83M | 3.62M | 4.39M | 6.46M | 8.52M | [{"date":"2020-04-30","value":44.91,"profit":true},{"date":"2021-04-30","value":42.52,"profit":true},{"date":"2022-04-30","value":51.55,"profit":true},{"date":"2023-04-30","value":75.77,"profit":true},{"date":"2024-04-30","value":100,"profit":true}] |
Operating Income | (3.83M) | (3.62M) | (4.39M) | (6.46M) | (6.52M) | [{"date":"2020-04-30","value":-382639500,"profit":false},{"date":"2021-04-30","value":-362298100,"profit":false},{"date":"2022-04-30","value":-439201400,"profit":false},{"date":"2023-04-30","value":-645549400,"profit":false},{"date":"2024-04-30","value":-652000800,"profit":false}] |
Total Non-Operating Income/Expense | (946.00) | 68.70K | 309.99K | 4.08M | 10.25M | [{"date":"2020-04-30","value":-0.01,"profit":false},{"date":"2021-04-30","value":0.67,"profit":true},{"date":"2022-04-30","value":3.02,"profit":true},{"date":"2023-04-30","value":39.77,"profit":true},{"date":"2024-04-30","value":100,"profit":true}] |
Pre-Tax Income | (3.83M) | (3.55M) | (4.24M) | (4.32M) | 333.76K | [{"date":"2020-04-30","value":-1146.59,"profit":false},{"date":"2021-04-30","value":-1064,"profit":false},{"date":"2022-04-30","value":-1270.11,"profit":false},{"date":"2023-04-30","value":-1293.13,"profit":false},{"date":"2024-04-30","value":100,"profit":true}] |
Income Taxes | 453.00 | 3.05K | (153.36K) | (1.94M) | (6.52M) | [{"date":"2020-04-30","value":14.87,"profit":true},{"date":"2021-04-30","value":100,"profit":true},{"date":"2022-04-30","value":-5034.87,"profit":false},{"date":"2023-04-30","value":-63607.98,"profit":false},{"date":"2024-04-30","value":-214051.48,"profit":false}] |
Income After Taxes | (3.83M) | (3.55M) | (4.09M) | (2.38M) | 6.85M | [{"date":"2020-04-30","value":-55.84,"profit":false},{"date":"2021-04-30","value":-51.86,"profit":false},{"date":"2022-04-30","value":-59.61,"profit":false},{"date":"2023-04-30","value":-34.7,"profit":false},{"date":"2024-04-30","value":100,"profit":true}] |
Income From Continuous Operations | (3.83M) | (3.55M) | (4.24M) | (4.32M) | 333.76K | [{"date":"2020-04-30","value":-1146.59,"profit":false},{"date":"2021-04-30","value":-1064,"profit":false},{"date":"2022-04-30","value":-1270.11,"profit":false},{"date":"2023-04-30","value":-1293.13,"profit":false},{"date":"2024-04-30","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Net Income | (3.83M) | (3.55M) | (4.09M) | (4.32M) | 333.76K | [{"date":"2020-04-30","value":-1146.72,"profit":false},{"date":"2021-04-30","value":-1064.91,"profit":false},{"date":"2022-04-30","value":-1224.16,"profit":false},{"date":"2023-04-30","value":-1293.13,"profit":false},{"date":"2024-04-30","value":100,"profit":true}] |
EPS (Diluted) | (3.67) | (2.36) | (0.81) | (0.21) | (0.92) | [{"date":"2020-04-30","value":-366.97,"profit":false},{"date":"2021-04-30","value":-235.65,"profit":false},{"date":"2022-04-30","value":-81,"profit":false},{"date":"2023-04-30","value":-20.91,"profit":false},{"date":"2024-04-30","value":-92.17,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PMCB | |
---|---|
Cash Ratio | 4.36 |
Current Ratio | 4.47 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PMCB | |
---|---|
ROA (LTM) | -4.76% |
ROE (LTM) | 47.88% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PMCB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.21 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.79 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PMCB | |
---|---|
Trailing PE | 1.73 |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.24 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
PEG | NM |
PharmaCyte Biotech Inc (PMCB) share price today is $1.53
Yes, Indians can buy shares of PharmaCyte Biotech Inc (PMCB) on Vested. To buy PharmaCyte Biotech Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PMCB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of PharmaCyte Biotech Inc (PMCB) via the Vested app. You can start investing in PharmaCyte Biotech Inc (PMCB) with a minimum investment of $1.
You can invest in shares of PharmaCyte Biotech Inc (PMCB) via Vested in three simple steps:
The 52-week high price of PharmaCyte Biotech Inc (PMCB) is $2.58. The 52-week low price of PharmaCyte Biotech Inc (PMCB) is $1.39.
The price-to-earnings (P/E) ratio of PharmaCyte Biotech Inc (PMCB) is 1.7274
The price-to-book (P/B) ratio of PharmaCyte Biotech Inc (PMCB) is 0.24
The dividend yield of PharmaCyte Biotech Inc (PMCB) is 0.00%
The market capitalization of PharmaCyte Biotech Inc (PMCB) is $10.66M
The stock symbol (or ticker) of PharmaCyte Biotech Inc is PMCB